Analyst Activity – Credit Suisse Group AG Reiterates Buy on Coherus Biosciences (NASDAQ:CHRS)

12

Analyst Ratings For Coherus Biosciences (NASDAQ:CHRS)

Today, Credit Suisse Group AG reiterated its Buy rating on Coherus Biosciences (NASDAQ:CHRS) with a price target of $38.00.

There are 6 buy ratings on the stock.

The current consensus rating on Coherus Biosciences (NASDAQ:CHRS) is Buy (Score: 3.00) with a consensus target price of $40.50 per share, a potential 116.00% upside.

Some recent analyst ratings include

  • 4/21/2017-Credit Suisse Group AG Reiterated Rating of Buy.
  • 3/14/2017-Maxim Group Reiterated Rating of Buy.
  • 2/1/2017-Robert W. Baird Reiterated Rating of Outperform.
  • 11/25/2016-Standpoint Research initiated coverage with a Buy rating.
  • 11/7/2016-Citigroup Inc Reiterated Rating of Buy.
  • 10/4/2016-Barclays PLC Reiterated Rating of Overweight.

Dividend information for Coherus Biosciences (NASDAQ:CHRS)

.
Recent Insider Trading Activity For Coherus Biosciences (NASDAQ:CHRS)
Coherus Biosciences (NASDAQ:CHRS) has insider ownership of 32.88% and institutional ownership of 64.52%.

  • On 4/3/2017 Alan C Herman, Insider, sold 11,333 with an average share price of $20.73 per share and the total transaction amounting to $234,933.09. View SEC Filing
  • On 1/25/2017 Jean-Frederic Viret, CFO, sold 3,900 with an average share price of $27.00 per share and the total transaction amounting to $105,300.00. View SEC Filing
  • On 12/16/2016 Jean-Frederic Viret, CFO, sold 3,900 with an average share price of $28.30 per share and the total transaction amounting to $110,370.00. View SEC Filing
  • On 12/8/2016 Mats Wahlstrom, Director, sold 53,583 with an average share price of $27.52 per share and the total transaction amounting to $1,474,604.16. View SEC Filing
  • On 12/1/2016 Alan C Herman, Insider, sold 11,333 with an average share price of $27.40 per share and the total transaction amounting to $310,524.20. View SEC Filing
  • On 10/21/2016 Jean-Frederic Viret, CFO, sold 3,900 with an average share price of $30.62 per share and the total transaction amounting to $119,418.00. View SEC Filing
  • On 10/3/2016 Alan C Herman, Insider, sold 11,333 with an average share price of $25.69 per share and the total transaction amounting to $291,144.77. View SEC Filing

About Coherus Biosciences (NASDAQ:CHRS)
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company’s product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Recent Trading Activity for Coherus Biosciences (NASDAQ:CHRS)
Shares of Coherus Biosciences closed the previous trading session at 18.75 up +0.10 0.54% with 524,167 shares trading hands.

An ad to help with our costs